Pricing Log in Create free account

Hemab Therapeutics Holdings, Inc. (COAG) vs First Tracks Biotherapeutics, Inc. (TRAX)

Hemab Therapeutics Holdings, Inc. and First Tracks Biotherapeutics, Inc. are both Biotechnology companies. Hemab Therapeutics Holdings, Inc. is the larger, with a market value of $2.1B against $1.9B — 1.1× the size. Across the 5 metrics below, Hemab Therapeutics Holdings, Inc. leads on 3 and First Tracks Biotherapeutics, Inc. on 2.

Valuation

Metric COAG TRAX Biotechnology median
P/E n/m n/m 10.26
P/S n/m n/m 9.18
P/B 3.03 10.89 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales n/m n/m 8.98
Earnings yield (117.82%) (11.24%) (34.89%)
Free cash flow yield (5.28%) (6.83%) (24.52%)

Profitability

Metric COAG TRAX Biotechnology median
Gross margin — — 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% 0.00% (50.12%)
Return on assets (31.79%) 0.00% (45.60%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric COAG TRAX Biotechnology median
Revenue growth (TTM) — — 6.26%
EPS growth (last fiscal year) — — 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric COAG TRAX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 35.85 9.16 4.89
Net debt to EBITDA — — 1.01

Dividend

Metric COAG TRAX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric COAG TRAX Biotechnology median
Market cap 2.13b 1.91b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack